dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.395405 | 18e7a64ad4314fefbf9862416ead9364 | (A) The combined sleeve of LCL-biceps femoris-PFL (blue arrowhead) with locking Krackow sutures in place (yellow arrow) which are passed through the fibular head. (B) The biceps femoris tendon (white arrow) repositioned onto the fibular head. LCL, lateral collateral ligament; PFL, popliteofibular ligament. | PMC9663643 | 10.1177_23259671221131817-fig2.jpg |
0.437065 | 9a7db4be76734bd48517c7d1eeedf08e | (A) Krackow sutures (blue arrow) are placed through the anterior tunnel of the fibular head. The sutures are not yet tensioned or tied. (B) Krackow sutures that have been tensioned and tied over the anteromedial tibial cortex. Double black arrow indicates the course of the LCL, the thin green arrow indicates the peroneal nerve, and the yellow arrowhead indicates the biceps femoris tendon. LCL, lateral collateral ligament. | PMC9663643 | 10.1177_23259671221131817-fig3.jpg |
0.431081 | 9ec640aef5d94a518d8999db37618816 | (A) MRI showing PLC avulsion injury with biceps femoris tendon (yellow arrowhead) attached to the avulsed fibular styloid fracture fragment (red arrow). (B) MRI at 3 months after repair demonstrating the healed biceps femoris tendon and fibular styloid (orange arrowhead). The white arrow represents the drill hole path through the fibular head and heading toward the anteromedial tibia. MRI, magnetic resonance imaging; PLC, posterolateral corner. | PMC9663643 | 10.1177_23259671221131817-fig4.jpg |
0.406803 | 28344267eb3d44dab9711dc53623f8b1 | (A) The location of injury to the LCL was observed in the following frequencies: 18% (n = 5) of injuries were femoral-sided injuries, 0% were a midsubstance tear, and 82% (n = 23) were an avulsion off of the fibular head. (B) The location of injury to the biceps femoris was observed in the following frequencies: 100% (n = 14) of injuries were an avulsion off of the fibular head and 0% were an injury at the myotendinous junction. (C) The location of injury to the popliteus tendon was observed in the following frequencies: 69% (n = 9) were femoral-sided injuries, 0% were midsubstance, and 31% (n = 4) were at the myotendinous junction. (D) The location of injury to the popliteofibular ligament was observed in the following frequencies: 100% (n = 12) of injuries were an avulsion off of the fibular head. Image adapted from Kahan JB, Li D, Schneble CA, et al. The pathoanatomy of posterolateral corner ligamentous disruption in multiligament knee injuries is predictive of peroneal nerve injury. Am J Sports Med. 2020;48(14):3541-3548. LCL, lateral collateral ligament. | PMC9663643 | 10.1177_23259671221131817-fig5.jpg |
0.437658 | 0d089f4c92e94434a0089b6b26823c09 | Posterolateral corner injury classification system according to Kahan et al.
7
The injuries were classified into 3 main classes based on location to the LCL: class P (proximal) femoral avulsion (n = 5, 18%), class M midsubstance tear (n = 0), and class D (distal) fibular avulsion (n = 23, 82%). Class D injuries were subclassified based on the number of structures avulsed from the fibular head: class D1 (n = 0), class D2 (n = 15, 65%), and class D3 (n = 8, 35%). Image adapted from Kahan JB, Li D, Schneble CA, et al. The pathoanatomy of posterolateral corner ligamentous disruption in multiligament knee injuries is predictive of peroneal nerve injury. Am J Sports Med. 2020;48(14):3541-3548. | PMC9663643 | 10.1177_23259671221131817-fig6.jpg |
0.431082 | dcb9d962bc084196a055552e2cf18b3a | Flowchart diagram representing children lost to follow-up and included in the final analysis and the reasons for a drop-out. | PMC9663913 | fped-10-959643-g001.jpg |
0.403089 | cafa626b3d5148ceaddbcdb5e85d12b9 | Cytotoxic effects of different concentrations of standard (drug) and isolated colchicine after
24-hours of treatment. A. On MCF-7 cells, B. On 4T1 cells,
and C. On fibroblast cells. Data are given as mean ± SE for each point of
three separate experiments, *; P<0.05, **; P<0.001 vs. control. | PMC9663959 | Cell-J-24-647-g01.jpg |
0.432107 | f18662b5b66949a79708aba620a29dfd | The growth inhibitory effect of different concentrations of isolated and standard colchicine
(drug) after 48 hours. A. On MCF-7 cells, B. 4T1 cells, and
C. Fibroblast cells. Data are given as mean ± SE for each point of
three separate experiments, *; P<0.05 and **; P<0.001 vs. control. | PMC9663959 | Cell-J-24-647-g02.jpg |
0.402422 | 4f5de4ff4a6543b9b847dabcbb5bbbca | mRNA expression of pro-apoptotic and anti-apoptotic genes. A.
P53, BAX, BCL-2 in MCF-7 cells, B.
p53, Bax, Bcl-2 in 4T1 cells. The expression of pro-apoptotic and
anti-apoptotic genes in both cell lines was determined by measuring mRNA levels using
real-time polymerase chain reaction (PCR). Data are given as mean ± SE for each point
of three separate experiments, *; P<0.01, **; P<0.05, ***;
P<0.001, between equal concentrations of colchicine and $; P<0.01, $$;
P<0.05, $$$; P<0.001, between different concentrations of colchicine.
C. Colchicine effects on the expression of BAX/BCL-2
in MCF-7 and 4T1 cells. Data are given as mean ± SE for each point of three separate
experiments. *; P<0.01, **; P<0.05, ***; P<0.001 vs. control and
$; P<0.01, $$; P<0.05, $$$; P<0.001 vs. equal concentrations of
isolated and standard colchicine (drug). | PMC9663959 | Cell-J-24-647-g03.jpg |
0.458085 | 7dab9b4c8a354a54ab761cbb15bc6e83 | Expression of pro-apoptotic and anti-apoptotic proteins and densitometric analysis.
A. The effects of colchicine on the expression of pro-apoptotic and
anti-apoptotic proteins in MCF-7 and 4T1 cells. Cells were exposed to the isolated and
standard colchicine (drug) at 0.5 and 1 µg/ml and 200 and 400 µg/ml, respectively for
24 hours. The protein expression of P53, Bax, Bcl-2, caspase-3 and -9 was determined
by Western blotting against controls, B. Densitometricy analysis of P53,
Bax, Bcl-2, Caspase-3 and -9 proteins in MCF-7 cell line, and C.
Densitometricy analysis in 4T1 cell line. Data are given as mean ± SE for each point
of three separate experiments. Different letters indicate a significant difference
(P<0.05) and the same characters indicate a non-significant difference between
the treatments (P>0.05). I; Isolated and D; Drug. | PMC9663959 | Cell-J-24-647-g04.jpg |
0.428085 | 34fed1d206184d7ca560590897fbadcb | Results of Fluorescence Microscope image and early and late apoptos of MCF-7 cells.
A. Untreated cells as the control group, B. Treated cells
with 0.5 µg/ml of standard colchicine (drug), C. Treated cells with 1
µg/ml of standard colchicine (drug), D. Treated cells with 0.5 µg/ml of
isolated colchicine, E. Treated cells with 1 µg/ml of isolated colchicine
(scale bar: 50 µm), and F. The results of early and late apoptosis in
MCF-7 cells determined by Annexin V-PI method. **; P<0.001 vs. control, and
$$; P<0.001 vs. equal concentrations of isolated and standard
colchicine (drug). | PMC9663959 | Cell-J-24-647-g05.jpg |
0.427629 | 52d0fa73a7574835b4bde92c4de05d14 | Results of Fluorescence Microscope image and early and late apoptos of 4T1 cells. A.
Untreated cells as control group, B. Treated cells with 200 µg/ml
of standard colchicine, C. Treated cells with 400 µg/ml of standard
colchicine (drug), D. Treated cells with 200 µg/ml of isolated
colchicine, E. Treated cells with 400 µg/ml of standard colchicine (drug)
(scale bar: 50 µm), and F. Results of early and late apoptosis in 4T1
cells determined by Annexin V-PI method. **; P<0.001 vs. control and
$$; P<0.001 vs. same concentration of isolated and standard
colchicine (drug). | PMC9663959 | Cell-J-24-647-g06.jpg |
0.403894 | 935bf95848634bfe8dae264eeb26f75e | Workstreams (WS) in the Life After Prostate Cancer Diagnosis (LAPCD) study. | PMC9664269 | bmjopen-2022-060861f01.jpg |
0.450818 | 15cac6bffaa34af99e24106a59977696 | Theory of change model. | PMC9664269 | bmjopen-2022-060861f02.jpg |
0.437532 | 0cecfcb720ae407e97d7db1971c09d41 | Summary of results. UAG, User Advisory Group. | PMC9664269 | bmjopen-2022-060861f03.jpg |
0.493705 | 7f14a01025f34ee2891e8c8f5934efc9 | General schematic diagram of common environmental factors associated with Alzheimer's disease. | PMC9664454 | d2ra05384e-f1.jpg |
0.434728 | 98a2b799e1354ea6bb3aaa27328320ce | Fabrication of optical chemosensors using (A) metal organic frameworks (MOFs) and (B) mesoporous silica (MSNs). | PMC9664454 | d2ra05384e-f2.jpg |
0.439021 | 5f10055843824db9b61e647aec405bb1 | Preparation of mesoporous silica as nanoporous carrier. Briefly, TEOS (tetraethoxysilane) is reacted with a cationic surfactant (e.g., CTAB) in water/acetone/diethyl ether solvent to form mesoporous silica nanospheres (MSNs). Filtration is then carried out followed by calcination at 550 °C. | PMC9664454 | d2ra05384e-f3.jpg |
0.409105 | b4c7d43065624cf8bf70eb1b0317d8ff | General schematic representation for fabrication of metal organic frameworks (MOFs) with different dimensions. | PMC9664454 | d2ra05384e-f4.jpg |
0.464596 | 0990057639434b6d9865a16ad6e99e2b | Preparation, properties and applications of metal organic frameworks. | PMC9664454 | d2ra05384e-f5.jpg |
0.437616 | 7cd796a793404fe6b979f87575dc558e | General schematic diagram of different immobilization approaches of organic probes on different carriers. | PMC9664454 | d2ra05384e-f6.jpg |
0.428815 | 1c8a6e89472c4090af85ccfa3e00d8f1 | (A) Schematic diagram for sensing Hg2+ ions using bis(diethylamino)-3oxospiro[isoindoline-1,9′-xanthen]-2ylcarbamothioyl)-4-butylbenzamide (BOICB) probe.94 (B) Schematic representation of fabrication of nanorod TAM optical chemosensors and interactions with Hg2+ ions under optimum conditions.95 (C) Representative design of the Nin-NH-MIL-101(Al) sensor applied for purification of water polluted with Hg(ii) ions and the reversible process by using 0.1 M thiourea solution (which can be repeated several times).96 Reproduced with permission from ref. 94–96. | PMC9664454 | d2ra05384e-f7.jpg |
0.525061 | e34c468a782049c4a2cd987ee45eddf9 | (A) General schematic presentation of optical chemosensors based on aluminosilica network platforms via direct functionalization with δ-tetrakis(1-methylpyridinium-4-yl)porphine ρ-toluenesulfonate for Cd(ii) ions detection.76 (B) Chelating ligand immobilized mesostructures Ia 3d aluminosilica for visualization and removal of Cd(ii).97 (C) The Zr-based metal–organic frameworks (UiO-66) with its micropore geometry for the visual detection, determination and removal of ultra-trace of some toxic metal ions such as Cd2+.98 (D) General steps of fabricating Cd2+ ion optical chemosensors built on mesoporous nanosphere silica for naked-eye determination of ultra-traces of Cd2+ ions.99 Reproduced with permission from ref. 69,97–99. | PMC9664454 | d2ra05384e-f8.jpg |
0.390804 | 37f9976fab7f4019b9d6555c4e57c81d | (A) General representation of fluorescent probe prepared based on amino-functionalized metal–organic frameworks (MOF-5-NH2) for the detection of Pb2+.100 (B) Ratiometric fluorescent (RF) probe CDs/QDs@ZIF-8 by encapsulating carbon dots (CDs) and thioglycolic acid modified CdTe quantum dots (QDs) into porous metal–organic frameworks (MOFs) for detection of Pb2+.101 (C) Phosphorescent sensor to monitor Pb2+ using metal–organic framework-5.102 Reproduced with permission from ref. 100–102. | PMC9664454 | d2ra05384e-f9.jpg |
0.451864 | ba0efa500ed24e5388f46d63db0f401f | XRD pattern of calcium titanate nanoparticles showing peaks at theta angles of 32.7º, 47.1°, 58.9°, and 69° | PMC9664598 | 12935_2022_2780_Fig1_HTML.jpg |
0.465351 | 42bb31c4e82a4419b5b9422438e8ef97 | Zeta Potential and Size distribution of calcium titanate nanoparticles | PMC9664598 | 12935_2022_2780_Fig2_HTML.jpg |
0.467546 | a29991f9b278458b916b79997760da59 | TEM image of calcium titanate nanoparticles | PMC9664598 | 12935_2022_2780_Fig3_HTML.jpg |
0.448761 | 40f8886f846d4b8b96741d7c415d2962 | Viability of cancer MCF-7 cells after exposure to five different concentrations of calcium titanate nanoparticles (0.01, 0.1, 1, 10 and 100 µg/ml) for 24 h or (0.1, 1, 10, 100 and 1000 µg/ml) for 72 h | PMC9664598 | 12935_2022_2780_Fig4_HTML.jpg |
0.416001 | 46d43a4659b44e598cac8300159ec086 | Examples for the scored Comet nuclei in MCF-7 cells showing nuclei with intact DNA (In) and other nuclei with different degree of damaged DNA damage (200 × magnification) | PMC9664598 | 12935_2022_2780_Fig5_HTML.jpg |
0.505523 | 061feb1d10d64590a7471a25fc6c8bf0 | Level of ROS within the control and treated MCF-7 cells with IC50/72 of calcium titanate nanoparticles ((200 × magnification) | PMC9664598 | 12935_2022_2780_Fig6_HTML.jpg |
0.435871 | e6bf7f7fbaa747beaa09072f00977516 | Expression levels of p53, Bax and Bcl2 genes in the control and treated MCF-7 cells with IC50/72 h of Calcium Titanate nanoparticles. Results are expressed as mean ± SD. *: Indicates statistical significant difference from the compared control at p < 0.05 using student t-test | PMC9664598 | 12935_2022_2780_Fig7_HTML.jpg |
0.472081 | 55e4c94262b14c5ab65edaf863b39fa6 | Cell cycle distribution of the control and treated MCF-7 cells with IC50/72 of calcium titanate nanoparticles | PMC9664598 | 12935_2022_2780_Fig8_HTML.jpg |
0.461868 | 6426cd9cd3d948cdb3ec27b2370a347f | Apoptosis induction in the control and treated MCF-7 cells with IC50/72 of calcium titanate nanoparticles. Q2-1 denotes necrosis phase; Q2-2 denotes late apoptosis phase, Q2-3 denotes normal viable cells and Q2-4 denotes early apoptosis phase | PMC9664598 | 12935_2022_2780_Fig9_HTML.jpg |
0.371581 | cc87953380f643a4bce6afe83c36e649 | Age at diagnosis of HbSS of the participants. | PMC9665090 | IANN_A_2129090_F0001_C.jpg |
0.532838 | 8f322e18204b40b2ad16563ec0a74657 | Steady state packed cell volume of participants. | PMC9665090 | IANN_A_2129090_F0002_C.jpg |
0.430643 | 9e709b75c1b44299b9474ef3dd9de1da | Number of hospital admission in a year in the participants. | PMC9665090 | IANN_A_2129090_F0003_C.jpg |
0.447228 | 49682dc27dac4047b5c8c46e3d40546e | Number of bone pain crisis per year in the participants. | PMC9665090 | IANN_A_2129090_F0004_C.jpg |
0.363162 | 4058607ce7b94e518d837d2045f956a8 | Complications of sickle cell anaemia in the participants. | PMC9665090 | IANN_A_2129090_F0005_C.jpg |
0.431122 | ced94c176860473ea9791db7c8525efb | Expanded SEIR model flowchart.Each compartment represents a distinct state of infection, with arrows indicating flows between compartments. | PMC9665358 | pone.0277521.g001.jpg |
0.461504 | 7c6e8e8e941f4a44942d5e8c9ede2209 | Model fits and long-term predictions.a) Median model fits to the 7-day moving average of daily confirmed case data, along with short-term predictions, assuming long-term immunity. The cases due to the alpha, delta, and other variants are given in red, green, and blue, respectively. b) Long-term forecasts of daily confirmed cases until February 2023. The 7-day moving average of confirmed case data is given in red. The median model predictions given estimates of social distancing measures and vaccination rate as of Sept. 24th 2021 are given by the black curve, while the model predictions given a full release of social distancing measures are given by the blue curve. The yellow and blue shading represent the 90% confidence intervals for these two scenarios. If the vaccination rate is increased by 1.5x, the median model prediction given social distancing measures estimated on Sept. 24th 2021 is given by the green dashed curve, while in the case of full release of social measures, it is given in magenta. The blue dashed line represents a full release of social measures on Mar. 1st 2021, when the fraction of immunity was much lower than present, which produces a peak of 250,000 daily confirmed cases (assuming social measures are not modified). c) Total proportion susceptible (blue), and total immune (black) over time. The proportion immune given estimates of social measures and vaccination as of Sept. 24th 2021 is given by the solid black line, while a full release of social measures is shown as a dashed black line. If the vaccination rate is increased by 1.5x, the proportion immune is represented by the red dashed line. The 90% confidence interval is shown as a yellow band. As of Sept. 24th 2021, 9% of the population were susceptible, while 90% were immune. d) Proportion of the population with natural immunity (red) along with the proportion of the population with vaccine-conferred immunity (blue). As of Sept. 24th 2021, the fraction of the population with natural immunity is 34%, while the fraction with vaccine-induced immunity is 56%. | PMC9665358 | pone.0277521.g002.jpg |
0.403261 | 3d3d2408c43546038d28a4845e29261f | Model predictions of hospitalizations and deaths.Median predictions of a) total hospitalizations and b) daily deaths over time. Several scenarios are shown. Median model predictions given estimates of social distancing measures and daily vaccination rate as of Sept. 24th 2021 are shown by the solid black curve, while the median model predictions given a full release of social measures is shown in blue. The 90% confidence interval for these two scenarios (social measures estimated on Sept. 24th 2021, and full release of social measures) are given by the yellow and blue bands, respectively. If vaccination rate is increased by a factor of 1.5x, the median model predictions are shown by the green curve when applying estimates of social measures as of Sept. 24th 2021 and shown in magenta under a full release of social measures. The daily hospitalization and death data is shown by the red circles. | PMC9665358 | pone.0277521.g003.jpg |
0.442687 | ab8de1c9bbce42f5887ebc521c240af5 | Scenarios of waning immunity.(Top row) Scenarios of waning immunity, given waning intervals of 1 year, 2.5 years, and 5 years. The median model predictions of confirmed cases given estimated social distancing measures as of Sept. 24th 2021 and release of social measures are given by the black and blue curves, respectively. The 90% confidence interval for the median case is given by the orange shading, while the confirmed case data is given in red. (Bottom row) Forecasts for total proportion susceptible (blue), and total immune (black) are shown over time. Solid curves represent the impact of maintaining social measures and vaccination rates as of Sept. 24th 2021, while the dashed curve denotes the effects for a full release of social measures. | PMC9665358 | pone.0277521.g004.jpg |
0.429622 | 900f7d0decda45ed82873a7d2fa62e8e | Model ensemble and probability of elimination over time, given long-term immunity.Ensemble of predictions of daily confirmed cases, and probability of elimination over time, assuming long-term immunity, given a) estimated social measures as of Sept. 24th, 2021 and b) after the full release of social measures. The predictions of the model ensemble (250 in total, see Methods) are represented by the thin curves in the background of the figure. Given the estimated social measures and vaccination rate as of Sept. 24th, 2021, the probability of fadeout is given by the blue curves, whereas increasing vaccination to 1.5x is presented by the green curves, respectively. If estimated social measures are continued along with the vaccination rate as of Sept. 24th 2021, 99% probability of elimination will be achieved on Nov. 13th 2021, while if social measures are fully released, 99% probability of elimination will be achieved on Nov. 22nd 2021. With a 1.5x increase in vaccination, the corresponding 99% probability of pandemic fadeout will be achieved on Nov. 8th 2021 and Nov. 19th 2021 for continuing with estimated social measures and given a release of social measures, respectively. Even though there is a significant probability of resurgence given a full release of social measures, the size of the wave is likely to be very small. | PMC9665358 | pone.0277521.g005.jpg |
0.434613 | c571df17ebe04300b1ab8a83ab3028a9 | Model ensemble and probability of elimination over time, given waning of immunity.Ensemble of predictions of daily confirmed cases, and probability of elimination over time, assuming waning of natural immunity over 2.5 years, given a) estimates of social measures as of Sept. 24th 2021 and b) after the full release of social measures. The predictions of the model ensemble (250 in total, see Methods) are represented by the thin curves in the background of the figure. For the estimated social measures and vaccination rate, the probability of fadeout is given by the blue curves. For these scenarios, the probability of elimination does not reach 50% until 2023. | PMC9665358 | pone.0277521.g006.jpg |
0.425746 | 0b54c7aa266747ecb92eaeb4a508e83f | Simulations of emerging variants.a) Median model predictions (black) fit to the 7-day moving average of daily confirmed cases in Florida to Sept. 24th 2021 (blue), given waning of immunity over 2.5 years. Confirmed case data from Sept. 24th to Feb. 14th 2022 is shown by the gray curve. Four scenarios of the emergence of a 4th variant are shown: 2x transmissibility of the original variants, emerging on November 1st (red, solid line), 1.5x transmissibility, emerging on November 1st (blue, solid line), 2x transmissibility, emerging on December 1st (red, dashed line), and 1.5x transmissibility, emerging on December 1st (blue, dashed line). b) Simulations of a 5th variant, emerging on Mar. 1st 2022 (blue), May 1st 2022 (red), July 1st 2022 (green), and Sept. 1st 2022 (magenta). Solid lines represent the case of a 5x increase in transmissibility compared to the original variant, while the dashed lines represent a 3.5x increase in transmissibility. | PMC9665358 | pone.0277521.g007.jpg |
0.563099 | 87e248128b6f4aee9d497acead67ef53 | Responders and countries. | PMC9666278 | can-16-1443fig1.jpg |
0.367238 | f932d710f77e4611974eb142ecd1944e | Availability of National Health Care System. | PMC9666278 | can-16-1443fig2.jpg |
0.499532 | 251c233a9c034d5da96303f38a7a4861 | Availability of National Cancer Registry. | PMC9666278 | can-16-1443fig3.jpg |
0.423544 | addd75dd4bd34c5abd67c7496219f112 | Availability of National Breast Screening Programme. | PMC9666278 | can-16-1443fig4.jpg |
0.493542 | 4af72a52f952412388a0ebdc98591bcf | Breast cancer management in dedicated or accredited breast centres with multidisciplinary care team. | PMC9666278 | can-16-1443fig5.jpg |
0.423566 | 395328c131c9469b9a0d3de508d88c06 | Frequency of breast screening. | PMC9666278 | can-16-1443fig6.jpg |
0.449687 | c913e15143a84804b0193c150b509267 | Proportion of patient undergoing breast conservation surgery. | PMC9666278 | can-16-1443fig7.jpg |
0.476222 | d480aed4a00049d5b45bf2b5fb575999 | Most important hurdles in offering breast reconstruction, if any. | PMC9666278 | can-16-1443fig8.jpg |
0.447587 | 49e98924245c466c8f1feeb761638dd0 | Mode of training in oncoplastic procedures. | PMC9666278 | can-16-1443fig9.jpg |
0.408785 | dce8ad065ce949c7894786b3fcc0c5ba | Knockdown of STING post-Golgi cofactors activates tonic IFN signaling.a A spatiotemporal map of selected STING cofactor candidates identified in the primary proteomic screen. Open, half-filled and filled circles indicate cofactors identified at 0.5 h, 4 h and 8 h after STING activation, respectively. b
lfnb1 mRNA expression in ligand activation assay and tonic activation assay c. Wild-type MEFs were transfected with specific siRNA against each of the 31 selected candidate cofactors. Then, knockdown cells were either simulated with HT-DNA (1 µg/mL, 4 h) then qRT-PCR for Ifnb1 expression b or directly measured Ifnb1 expression without stimulation c. Fold-changes were determined by normalizing to control siRNA in either assay. Primary data are shown in Supplementary Fig. 1. d qRT-PCR analysis of resting-state lfnb1 and Ccl4 (an ISG) mRNA expression after control, Sec24c or Gcc2 siRNA knockdown in wild-type MEFs. n = 4. e ELISA analysis of mouse IFN-β in the supernatant after control, Sec24c or Gcc2 siRNA knockdown followed by DXMAA stimulation (50 µM, 8 h). n = 3. f Confocal microscopy images of STING colocalization with Golgi. StingKO MEFs stably expressing HA-STING were transfected with control, Sec24c or Gcc2 siRNA followed by mock or HTDNA stimulation (1 µg/mL, 1.5 h). HA-STING in green, GM130 (a Golgi marker) in red and DAPI in blue. Scale bar, 20 µm. Data are representative of at least three independent experiments. Data (d and e) are shown as mean ± s.e.m. P values were determined by One-way ANOVA. | PMC9666523 | 41467_2022_33765_Fig1_HTML.jpg |
0.432338 | d4f06718f2eb43b99aae69c0b61e7e92 | GCC2 is required for STING Golgi-exit.a A diagram of Golgin family members at the trans-Golgi network (TGN). b qRT-PCR analysis of tonic (left) or ligand-activated (right) lfnb1 mRNA expression after mock knockdown (siCtrl) or specific siRNA knockdown of Gcc1, Gcc2, Golga1, or Golga4 in wild-type MEFs. n = 3. c A heatmap showing expression of indicated ISGs (right) at the resting-state in Gcc2WT and Gcc2KO MEFs after control, Sting, Mavs siRNA knockdown. d Western blot analysis of STING signaling kinetics. Gcc2WT and Gcc2KO MEFs were stimulated with HTDNA (1 µg/mL) for indicated times (top). Quantification of relative Sting protein abundance (normalized to Tubulin, then set 0 h value to 1) are shown on the right. p-Sting, p-Tbk1, and p-Irf3 are key phosphorylation events of the STING signaling pathway. e ELISA analysis of mIFN-β in the supernatant in Gcc2WT and Gcc2KO MEFs 24 h after HSV-GFP infection (m.o.i. = 1). n = 4. f HSV-1-GFP infection in Gcc2WT and Gcc2KO MEFs. Top, representative FACS plot of GFP expression 24 h after HSV-1-GFP infection (m.o.i. = 1). Lower panels, percentage of GFP+ cells (lower left), GFP MFI (Mean fluorescence intensity, lower middle) and HSV-1 titers in the supernatant (lower right) in Gcc2WT and Gcc2KO MEFs. g–i Confocal microscopy analysis of endogenous STING trafficking and signaling. Gcc2WT or Gcc2KO MEFs were stimulated with HT-DNA (1 µg/mL) for indicated times (top). Cells were then stained for endogenous STING (green) and Golgi marker GM130 (red) (g, top). Quantification of fluorescence intensity of endogenous STING in the Golgi (GM130+ area) using Fiji (g, bottom). A similar set of cells were stained for p-Tbk1 and p-Irf3 (images in Supplementary Fig. 3e, f). Quantification of fluorescence intensity of endogenous p-TBK1 (h) and p-IRF3 (i) in Gcc2WT and Gcc2KO MEFs are shown. The colored area corresponds to Golgi-dwell time. n = 3. Data are representative of at least three independent experiments. At least 14 cells in two different views were analyzed (g–i). Data (b, e and g–i) are shown as mean ± s.e.m. P values were determined by one-way ANOVA (b and e) or by two-way ANOVA (g–i). | PMC9666523 | 41467_2022_33765_Fig2_HTML.jpg |
0.426776 | d1e1a40f0b6b403bbe1013eeb5e79ffc | Temperature-mediated slowdown of trafficking at the Golgi enhances STING signaling.a A diagram of expected STING trafficking at 37 °C and 20 °C. Top, at normal cell culture temperature (37 °C), STING activation triggers trafficking from the ER to Golgi then to endolysosomes. Bottom, lowering the temperature to 20 °C slows down post-Golgi vesicle trafficking, leading to STING accumulation on the Golgi. b Western blot analysis of STING signaling kinetics. Wild-type MEFs were first acclimated in 37 °C or 20 °C then stimulated with HT-DNA (1 µg/mL) for indicated times (top) while remaining at the same temperature. Control experiments with DMXAA or poly(I:C) stimulation are shown in Supplementary Fig. 5. c and d Confocal microscopy analysis of endogenous STING trafficking and signaling. Wild-type MEFs were stimulated with HT-DNA (1 µg/mL) while incubated at 37 °C or 20 °C. Endogenous STING trafficking (c, images on top, quantifications at the bottom) and signaling activation (d, p-TBK1 quantification on top, images at the bottom) were analyzed as in Fig. 2g, h. Scale bar, 20 µm. n = 3. Data are representative of at least three independent experiments. At least 17 cells in two different views were analyzed (c, d). Data (c, d) are shown as mean ± s.e.m. P values were determined by Two-way ANOVA (c, d). | PMC9666523 | 41467_2022_33765_Fig3_HTML.jpg |
0.410378 | db02e6e00c404b8bb2405e651954a902 | Both cGAS and STING are required for tonic IFN signaling in Gcc2-KO cells.a, b Western Blot (a) and qRT-PCR (b) analysis of tonic IFN signaling in Gcc2WT, Gcc2KO, Gcc2KOSTINGKO, and Gcc2KOcGASKO MEFs. Two independent CRISPR/Cas9 knockout clones of each genotype are included. p-Sting, p-Tbk1, and p-Stat1 are key phosphorylation events of the STING signaling pathway (a). Expression of IFN genes and ISGs are shown in a heatmap (b, left) and representative bar graphs (b, right). n = 3. c, d Western Blot (c) and qRT-PCR (d) analysis of tonic IFN signaling in Gcc2WT, Gcc2KO, Gcc2KOcGASKO MEFs reconstituted with vector control, wild-type cGAS, E225A/D227A cGAS (enzymatic-dead mutant), K407A/K411A cGAS (DNA-binding mutant). Cells were analyzed as in a, b. n = 3. e, f Western Blot (e) and qRT-PCR (f) analysis of tonic IFN signaling in Gcc2WT, Gcc2KO, Gcc2KOSTINGKO MEFs reconstituted with vector control, wild-type STING, R238A/Y240A STING (ligand-binding mutant), S366A STING (IFN signaling mutant). Cells were analyzed as in a, b. n = 3. g, h qPCR analysis of mtDNA content (g) and qRT-PCR analysis of tonic IFN signaling (h) in two independent clones of Gcc2WT, Gcc2KO with or without mtDNA depletion by EtBr. n = 3. i Intracellular cGAMP level in Gcc2WT and Gcc2KO cells mock treated or stimulated with HT-DNA. n = 8. j qPCR analysis of indicated cytoplasmic DNA species in Gcc2WT and Gcc2KO cells. n = 5. Data are representative of at least three independent experiments. Data (b, d, f, and g–j) are shown as mean ± s.e.m. P values were determined by one-way ANOVA (b, d, f, and g–j). | PMC9666523 | 41467_2022_33765_Fig4_HTML.jpg |
0.413495 | 7c9520a1cba24fd290db92e230e4a605 | cGAS drives STING signaling to maintain a basal state of immune defense.a, b qRT-PCR analysis of baseline immune gene expression in cGASWT and cGASKO mouse heart or BMDMs (n = 3). Heatmaps of multiple ISGs are shown in a. Representative bar graphs are shown in b. c, d Western Blot (c) and qRT-PCR (d) analysis of tonic IFN signaling in cGASWT and cGASKO MEFs. Two independent clones of cGASWT and cGASKO MEFs were shown. p-Sting, p-Tbk1 and p-Stat1 are key phosphorylation events of the STING signaling pathway (c). Expression of ISGs are shown in a heatmap (d, left) and representative bar graphs (d, right). n = 3. e, f Western blot (c) and qRT-PCR (d) analysis of tonic IFN signaling in cGASWT and cGASKO MEFs reconstituted with vector control, wild-type cGAS, E225A/D227A cGAS (enzymatic-dead mutant), K407A/K411A cGAS (DNA-binding mutant). Cells were analyzed as in c, d. n = 3. Data are representative of at least three independent experiments. Data (b, d, and f) are shown as mean ± s.e.m. P values were determined by one-way ANOVA (b, d, and f). | PMC9666523 | 41467_2022_33765_Fig5_HTML.jpg |
0.44125 | add7cba20c824ee0a097b4ea6a3c6d99 | RAB14 and other Rabs mediate STING post-Golgi trafficking.a qRT-PCR analysis of tonic Ifnb1 mRNA expression in StingWT or StingKO MEFs after siRNA knockdown of indicated Rab GTPases (bottom). Solid red bars indicate siRNAs that induce STING-dependent IFN signaling. n = 3. b Co-immunoprecipitation analysis of STING:Rab interaction. HEK293T cells were transfected with FLAG-Sting and various HA-Rab GTPases (as indicated on top), IP with the FLAG antibody and blotted with indicated antibody on the right. Percentages of IP/Input are shown on the bottom. Note the expression level of Rab14 plasmid is low in whole cell lysate but IP/Input% is high. c A heatmap showing expression of ISGs in Rab14WT, Rab14KO, Rab14KOStingKO-pool, and Rab14KOMavsKO-pool MEFs. Bar graphs are shown in Supplementary Fig. 7g. d Western blot analysis of STING signaling kinetics in Rab14WT and Rab14KO MEFs. Cells were stimulated with DMXAA (10 µg/mL) for indicated times (top) and blotted for total- and phosphor-proteins as indicated on the right. Quantification of relative Sting protein abundance (normalized to Tubulin, then set 0 h value to 1) are shown on the right. e Confocal microscopy analysis of endogenous STING trafficking in Rab14WT and Rab14KO MEFs. Cells were stimulated with DMXAA (10 µg/mL) and analyzed as in Fig. 2g. Endogenous STING in green and GM130 (a Golgi marker) in red. Scale bar, 20 µm. n = 3. Data are representative of at least three independent experiments. At least 37 cells in two different views were analyzed (e). Data (a and e) are shown as mean ± s.e.m. P values are determined by One-way ANOVA (a) or by Two-way ANOVA (e). | PMC9666523 | 41467_2022_33765_Fig6_HTML.jpg |
0.384811 | c5760c5a805142878e4e1984ec27c5d1 | Gcc2−/− mice develop STING-dependent serologic autoimmunity.a A heatmap showing IgM autoantibody array analysis of Gcc2+/+, Gcc2−/−, and Gcc2−/−Sting−/− mouse serum (6-month-old). n = 5. b Representative bar graphs of elevated IgM autoantibodies in Gcc2+/+, Gcc2−/− and Gcc2−/−Sting−/− mouse serum (6-month-old). n = 5. Data are shown as mean ± s.e.m. P values are determined by one-way ANOVA, ns, not significant. | PMC9666523 | 41467_2022_33765_Fig7_HTML.jpg |
0.498617 | 26962e3d20784c6393b5666a9faef2c7 | Gcc2-KO and Rab14-KO induce anti-tumor immunity.a B16 tumor growth in wild-type mice. Left, Western blot analysis of CRISPR/Cas9 knockout pooled B16 cells. Right, tumor volumes of wild-typepool, Sec24KO-pool, Gcc2KO-pool, Rab14KO-pool, or Npc1KO-pool B16 melanoma cells after subcutaneous injection in wild-type mice. b Wild-type, Gcc2KO and Rab14KO B16 cell proliferation analysis by IncuCyte. Representative single-cell CRISPR/Cas9 knockout clones are shown. c Wild-type, Gcc2KO and Rab14KO B16 tumor growth in wild-type mice. Left, mean tumor volume. Middle, individual mouse tumor growth curve. Right, Kaplan–Meier survival curve. d, e Wild-type, Gcc2KO and Rab14KO B16 tumor growth in Rag1−/− mice (d) and Ifnar1−/− mice (e). Left, mean tumor volume, Right, Kaplan–Meier survival curve. Data in b, c are representative of two independent experiments and in d, e are pooled from two independent experiments. Data (a–e) are shown as mean ± s.e.m. P values are determined by two-way ANOVA in (a–e). ns, not significant. Mantel-Cox tests were used for survival studies. | PMC9666523 | 41467_2022_33765_Fig8_HTML.jpg |
0.417534 | 56beca3e90a74fb0a36a83d13e17b5f7 | An overall model.Homeostatic cGAS activity drives STING trafficking that supports the basal level of immune defense and maintains a healthy state. cGas−/− cells and mice have lowered basal immune defense, leading to infection risk. Interruption of STING post-Golgi trafficking by Gcc2−/− and Rab14−/− leads to tonic IFN activation, increased autoimmunity and anti-tumor immunity. | PMC9666523 | 41467_2022_33765_Fig9_HTML.jpg |
0.425968 | 8036accf4dd54967a3b3412348574d8f | Nature-based thinking as a theoretical lens for participatory assessment of urban NBS.The photo was taken by Arjen Buijs | PMC9666616 | 13280_2022_1772_Fig1_HTML.jpg |
0.453238 | d15606ca56264775ae7e8ff59857b4a0 | The continuum of evidence by DeMeo et al. (2015) (authors’ interpretation) | PMC9666616 | 13280_2022_1772_Fig2_HTML.jpg |
0.486268 | 077334b6affc42d890143f556057f1c3 | Stages in participatory monitoring and assessment | PMC9666616 | 13280_2022_1772_Fig3_HTML.jpg |
0.444251 | 055cc2eec4504862a59afd5a1dd3c0a9 | Criteria for politicised and contextualised assessment applied at the level of the full set of indicators (Step 5 of the action framework) | PMC9666616 | 13280_2022_1772_Fig4_HTML.jpg |
0.487771 | d8f175f1eef3471182c75767c227e42c | Functional scheme. The study consists of several steps: from data collection to various tests to evaluate the model | PMC9667561 | 12859_2022_5038_Fig1_HTML.jpg |
0.387049 | 8ab787082bc04f7c902052cf0dff63dc | Session 1 survey. The figure represents the boxes of session 1 in which one is asked to list the characteristics of the patient and the disease and comment on them | PMC9667561 | 12859_2022_5038_Fig2_HTML.jpg |
0.44369 | 8876b793963f4f6c88c4db930b679217 | Session 2 survey. The figure depicts the questions in session 2 for each category of surgical techniques and comments on them | PMC9667561 | 12859_2022_5038_Fig3_HTML.jpg |
0.386121 | e5eeecc3d46d48788e7862983bbe8dcc | Session 3 survey. The figure shows the demands of session 3. It represents the opportunity to list the estimated results in daily clinical practice and to comment on them | PMC9667561 | 12859_2022_5038_Fig4_HTML.jpg |
0.470015 | ef3469fe725f46e591af1fcc933c0b20 | Model architectures. The CBOW architecture predicts the current word based on the context and the Skip-gram predicts surrounding words given the current word | PMC9667561 | 12859_2022_5038_Fig5_HTML.jpg |
0.444006 | cfb04bd3a4264785ae7af3ffba595912 | Web Graphic User Interface of ETHOS. This figure represents the GUI of ETHOS, which allows the execution of various analyses. In the center of the figure, the available analyses. On the left-hand side at the bottom of the figure is the table showing the analysis results | PMC9667561 | 12859_2022_5038_Fig6_HTML.jpg |
0.502963 | e36f48a690f84aeda73712cec252065d | Infiltrative basal cell carcinoma in the supra-alar region of the nose. As seen, the lesion is widespread and crusted | PMC9667695 | tao-60-155-g1.jpg |
0.49986 | f07fd4e3efcf46b5af87bdec73521a83 | Preparing the flap: The midline of both eyebrows was marked and an approximately a 2-cm area was identified as the estimated pedicle region starting from 2 (1.7–2.2) cm laterally | PMC9667695 | tao-60-155-g2.jpg |
0.446075 | dbf801a2b2814d8db49d5d287ae468f0 | (a-b) Creating template from the intact side using suture foil, (c) modifying template according to the defect area, (d) using template for designing the flap | PMC9667695 | tao-60-155-g3.jpg |
0.434337 | 84a99f8751a54e3c8a6ee27f2cc466b3 | (a) Using the conchal cartilage to reconstruct the alar cartilage, (bd) shaping the conchal cartilage as an alar cartilage (e) applying the shaped cartilage to the defect area, (f) final status of the flap | PMC9667695 | tao-60-155-g4.jpg |
0.450796 | 2185b35a94e54e13a305d79067a6e806 | View of the patient eight weeks after pedicle cutting and 13 weeks after the first operation | PMC9667695 | tao-60-155-g5.jpg |
0.493004 | 0773837680de43ce99411b83fd6252ae | Daily rainfall (mm), temperature (°C), and incident radiation (MJ m-2 day-1) during the summer season of maize and soybean in 2018, 2019, and 2020. | PMC9667818 | fpls-13-1006720-g001.jpg |
0.427899 | ccf337817dcf45d0b35cc10adb489fa3 | Field demonstration of maize/soybean strip intercropping system. (A) Intercrops were at the vegetative growth stage, and (B) Intercrops were at the reproductive growth stage (Photos: Muhammad Ali Raza). Location: Punjab Province, Pakistan. | PMC9667818 | fpls-13-1006720-g002.jpg |
0.444601 | 3627606ef98d465e8e17858395efdcf2 | Leaf area index of maize (A–C) and soybean (D–F) in response to different maize planting densities (6 maize plants m-2, low, D1; 8 maize plants m-2, medium, D2; and 10 maize plants m-2, high, D3) under maize/soybean strip intercropping. Bars show ± standard errors (n = 3). The different lowercase letters within a bar show a significant difference (p < 0.05) among treatments. The M and S represent the sole maize and soybean, respectively. | PMC9667818 | fpls-13-1006720-g003.jpg |
0.404003 | 7a8f19115eeb4a1fb95e65e77204091b | Dry matter of maize (A–C) and soybean (D–F) in response to different maize planting densities (6 maize plants m-2, low, D1; 8 maize plants m-2, medium, D2; and 10 maize plants m-2, high, D3) under maize/soybean strip intercropping. Bars show ± standard errors (n = 3). The different lowercase letters within a bar show a significant difference (p < 0.05) among treatments. The M and S represent the sole maize and soybean, respectively. | PMC9667818 | fpls-13-1006720-g004.jpg |
0.397827 | 0d8c15f16fc342cd892029e63d245524 | Three years average grain yield of maize (A), soybean (B), total grain yield (C) in response to different maize planting densities (6 maize plants m-2, low, D1; 8 maize plants m-2, medium, D2; and 10 maize plants m-2, high, D3) under maize/soybean strip intercropping. Bars show ± standard errors (n = 3). The different lowercase letters within a bar show a significant difference (p < 0.05) among treatments. The M and S represent the sole maize and soybean, respectively. | PMC9667818 | fpls-13-1006720-g005.jpg |
0.484871 | bcfa861ae75142869f523f027e7cde1e | Geographic location and odds of National Comprehensive Cancer Network (NCCN) treatment nonadherence for women diagnosed with early-stage ovarian cancer (OC). The fully adjusted effect of geographic location on the odds of receiving care that did not adhere to the NCCN treatment guidelines among women with early-staged OC (stages I and II) is shown. Models are adjusted for insurance status, age, race and ethnicity, socioeconomic status, marital status, tumor characteristics, Charlson Comorbidity Score, year of diagnosis, treatment at a high-volume hospital, proximity of closest high-volume hospital, and distance traveled to receive care. Statistically significant locations are outlined by contour lines. | PMC9667974 | pkac067f1.jpg |
0.428351 | ef4ac97595504a668c09777ddf6ebcb7 | Geographic location and odds of National Comprehensive Cancer Network (NCCN) treatment nonadherence for women diagnosed with advanced-staged ovarian cancer (OC). The fully adjusted effect of geographic location on the odds of receiving care that did not adhere to the NCCN treatment guidelines among women with advanced-staged OC (stages III and IV) is shown. Models are adjusted for insurance status, age, race and ethnicity, socioeconomic status, marital status, tumor characteristics, Charlson Comorbidity Score, year of diagnosis, treatment at a high-volume hospital, proximity of closest high-volume hospital, and distance traveled to receive care. Statistically significant locations are outlined by contour lines. | PMC9667974 | pkac067f2.jpg |
0.422421 | af3e03d517e74b6aa63c7dc413283660 | Time series of geographic risk of National Comprehensive Cancer Network (NCCN) treatment nonadherence for women diagnosed with ovarian cancer in California. The fully adjusted effect of geographic location on women’s risk of receiving care that did not adhere to the NCCN treatment guidelines over time and by early (stages I and II) vs advanced stages (stages III and IV) is shown. We examined 7 periods that overlapped by 2 years over a 22-year period. The last period, 2014-2017, is consistent with the implementation of all the Affordable Care Act initiatives. Models are adjusted for insurance status, age, race and ethnicity, socioeconomic status, marital status, tumor characteristics, Charlson Comorbidity Score, year of diagnosis, treatment at a high-volume hospital, proximity of closest high volume hospital, and distance traveled to receive care. Statistically significant locations are outlined by contour lines. | PMC9667974 | pkac067f3.jpg |
0.443048 | 8293d6e4b727427fbb6777329866f685 | Participant flow diagram. | PMC9668014 | bmjopen-2022-066511f01.jpg |
0.413411 | d4c5fa897dc84d3c9a73119caa47b066 | Bounding boxes as visual warnings used in XP3 | PMC9668227 | 42979_2022_1455_Fig10_HTML.jpg |
0.441795 | daf18de644884655a2b095b844f85944 | Mean TLX scores per type of modality | PMC9668227 | 42979_2022_1455_Fig11_HTML.jpg |
0.482304 | 232c00c767354f63855aaf6292882740 | The experimental procedure | PMC9668227 | 42979_2022_1455_Fig1_HTML.jpg |
0.390583 | 8fe92392844445f5b716b35f73420bb0 | The lab setup used in experiment 1 | PMC9668227 | 42979_2022_1455_Fig2_HTML.jpg |
0.367212 | 1f3bcd05afd147b3b2a73aff1ee22297 | Self-reported attitude toward AVs | PMC9668227 | 42979_2022_1455_Fig3_HTML.jpg |
0.421384 | 49c1d6a0d3184c9799927a5e7269d412 | Visual warnings used in XP1 | PMC9668227 | 42979_2022_1455_Fig4_HTML.jpg |
0.410713 | a85053f8821b43e2912b15fc01db4e4a | Visual warnings used in XP2 | PMC9668227 | 42979_2022_1455_Fig5_HTML.jpg |
0.434157 | 8d9d5b2428404bcf9b7e13ecab1db53a | Mean UEQ scores between XP1, XP2, and XP3 | PMC9668227 | 42979_2022_1455_Fig6_HTML.jpg |
0.437229 | 60ecf21ebf074126889b56b96f8e6cc1 | Comparison of SUS scores between XP1 and XP2 | PMC9668227 | 42979_2022_1455_Fig7_HTML.jpg |
0.481223 | 20b2e4e74e90437095d6fa33b7b8e843 | Correlation coefficient charts per condition between TLX scores and SUS scores in XP2 | PMC9668227 | 42979_2022_1455_Fig8_HTML.jpg |
0.449854 | f951406735484f07b3c1ce84bad826dd | TTS dashboard for the wizard used in XP3 | PMC9668227 | 42979_2022_1455_Fig9_HTML.jpg |
0.404782 | b3c043c33cc147f39d684c5212b328c4 | (a) CD spectra of HT-200 °C l-lysine in water at four different pHs (2.5, 7.3, 9.7 and 13) as a function of the temperature between 80 and 96 °C (measuring steps, 2 °C in heating and cooling). (b) Selected smoothed spectra from the figure a overlapped to a CD spectrum (reduced by 10 folds) of a protein with a secondary structures formed by 16% of α-Helix, 33% β-Strand, 21% Turn, and 30% Unordered. The simulation (grey dashed line) has been performed using a CONTINN algorithm11,23,24 of B23 CDApps10 and Leucyl–Leucine (Leu–Leu) (dashed red). (c) CD spectra of Leucyl–Leucine in ethanediol/H2O (2:1) at − 110 °C (blue), 26 °C (grey) 80 °C (red) and l-lysine at pH 7.3 at 20 °C in H2O (dashed grey)9. | PMC9668811 | 41598_2022_24109_Fig10_HTML.jpg |
0.430765 | 6a2325d73e6048619626d352ea130da7 | Size distribution by intensity of Dynamic Light Scattering of HTT-130 °C PLL (a) and HTT-200 °C (b) using as precursors the l-lysine aqueous solutions at pH 2.5, 7.3, 9.7 and 13. | PMC9668811 | 41598_2022_24109_Fig11_HTML.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.